Gina Kolata
Gina Kolata is a New York Times reporter focused on diseases and treatments. She writes about the discovery of treatments, their effects on people, and the ethical dilemmas that arise from them. Her work often involves telling personal stories of patients, doctors, and researchers to provide a human face to medical advances and failures. Kolata has a master's degree in applied mathematics from the University of Maryland and spent a year and a half studying molecular biology at M.I.T., but her real training came from speaking to researchers and patients. She has received several awards for her work, including being twice a Pulitzer finalist. Kolata is committed to The New York Times's ethical guidelines, avoiding conflicts of interest, treating those she interviews with respect, and not letting her personal views infuse her reporting.
66%
The Daily's Verdict
This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.
Bias
85%
Examples:
- Gina Kolata tends to present information in a balanced manner. However, there are instances where she presents a new or promising method as such when it has been around for some time.
- She sometimes relies on sources that have potential conflicts of interest or do not provide enough context for the reader.
Conflicts of Interest
67%
Examples:
- However, she generally does a good job of disclosing these potential conflicts.
- There are instances where Kolata's articles have potential conflicts of interest, such as reporting on a drug that her family has invested in.
Contradictions
85%
Examples:
- In some instances, Kolata's articles contain contradictions where she presents information that goes against previously established knowledge or facts.
- She sometimes reports on studies or treatments without fully considering potential contradictions to existing research.
Deceptions
43%
Examples:
- However, these instances are relatively rare and she generally presents information in an honest and straightforward manner.
- In some cases, Kolata's articles contain deceptive practices such as misleading statements or presenting information out of context.
Recent Articles
GLP-1: A Game Changer in Obesity Therapy and Beyond
Broke On: Saturday, 15 June 2024GLP-1, a satiety hormone discovered in groundbreaking research, shows promise for obesity therapy and type 2 diabetes remission. GLP-1 drugs have led to weight loss and improved cardiovascular health, despite some side effects. Ongoing research aims to enhance their efficacy and expand their applications beyond obesity. 
Lixisenatide Promising in Slowing Parkinson's Disease Progression, Study Finds
Broke On: Friday, 05 April 2024A diabetes drug has shown promise in slowing the progression of symptoms associated with Parkinson's disease, according to a new study published in The New England Journal of Medicine. Lixisenatide, which is similar to drugs such as Ozempic and Wegovy, slowed the progression of motor disability in patients with early-stage Parkinson's disease after 12 months. 
The Dangers of Weight Loss Drugs: Ozempic and Mounjaro Lawsuits Highlight Side Effects Risk
Broke On: Sunday, 31 March 2024Weight loss drugs Ozempic and Mounjaro have been linked to harsh side effects, including intestinal blockage, nausea, vomiting and abdominal pain. The FDA has placed a warning on their labels about these risks. However, these medications don't address the root causes of weight gain. It is important to consult with a healthcare professional before starting any new medication or diet plan. 
Colorectal Cancer: A Growing Threat Among Young People and Why You Should Get Screened Early
Broke On: Saturday, 16 March 2024Colorectal cancer, affecting the colon and rectum, is a common type of cancer among men under 50. It has been increasing in frequency among young people. The American Cancer Society recommends screening starting at age 45 or sooner without family history or symptoms. Blood Test for Colorectal Cancer: A Promising New Screening Tool?
Broke On: Wednesday, 13 March 2024A new study published in The New England Journal of Medicine found that a blood test for colorectal cancer was 83% accurate for detecting malignancies. This is similar to at-home stool tests, but the blood test has several advantages over other methods: it's less invasive and more acceptable to patients than colonoscopy and stool tests. The study used circulating tumor DNA from blood samples to develop the test. 
Blue Zones: How Ikaria's Residents Live Longer and Healthier with the Mediterranean Diet, Probiotics, Naps and Socializing
Broke On: Saturday, 10 February 2024How to Boost Your Brain Health Like the Blue Zones Residents :max_bytes(150000):strip_icc():focal(733x306:735x308)/king-charles-rishi-sunak-020624-4-394aa9ff57014810b138f93a47d89986.jpg)
King Charles of the United Kingdom Diagnosed with Cancer, Postpones Public-Facing Duties and Engagements for Treatment
Broke On: Tuesday, 06 February 2024King Charles of the United Kingdom has been diagnosed with cancer and will have to postpone public-facing duties while he receives treatment. President Joe Biden wished him a swift recovery. 
Tirzepatide Lowers Blood Pressure in Adults with Obesity: Study Findings
Broke On: Monday, 05 February 2024A new study found that the weight loss medication tirzepatide significantly lowered blood pressure in adults with obesity who took it for 36 weeks. Participants taking 5 mg of tirzepatide had an average systolic blood pressure reduction of 7.4 mm Hg, while those taking 10 mg and 15 mg had reductions of respectively.